{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T17:28:48Z","timestamp":1790702928153,"version":"4.1.0"},"reference-count":22,"publisher":"Oxford University Press (OUP)","issue":"3","license":[{"start":{"date-parts":[[2022,11,29]],"date-time":"2022-11-29T00:00:00Z","timestamp":1669680000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100015661","name":"UCB Pharma","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100015661","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Robert Jones"},{"name":"UCB Pharma in accordance with Good Publication Practice"},{"DOI":"10.13039\/501100000272","name":"NIHR","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000272","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,2,22]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Discontinuation of biologics is common among patients with psoriasis due to treatment failure or adverse events. To achieve improvements in disease management, patients and clinicians may choose to switch biologics.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Objectives<\/jats:title>\n                  <jats:p>To evaluate the efficacy and safety of switching to bimekizumab from adalimumab, ustekinumab and secukinumab.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>Data are reported for up to 80 weeks after patients switched to bimekizumab from adalimumab at week 24 in BE SURE, ustekinumab at week 52 in BE VIVID [upon entry into the BE BRIGHT open-label extension (OLE)] and secukinumab at week 48 in BE RADIANT (upon entry into the BE RADIANT OLE). Efficacy outcomes are reported by number of weeks after switching to bimekizumab and were split based on whether patients had achieved a \u2265\u00a090% improvement from baseline in Psoriasis Area and Severity Index (PASI 90) at the time of switch. Treatment-emergent adverse events (TEAEs) are reported using exposure-adjusted incidence rates (EAIRs) per 100 patient-years. Trial registration: BE SURE (NCT03412747), BE VIVID (NCT03370133), BE BRIGHT (NCT03598790), BE RADIANT (NCT03536884).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Rapid and durable improvements in clinical responses and benefits in health-related quality of life were observed among PASI 90 nonresponders who switched to bimekizumab. Most PASI 90 nonresponders achieved PASI 90 4 weeks after switching to bimekizumab from adalimumab (67%), ustekinumab (79%) and secukinumab (53%). After 48 weeks of bimekizumab, 91%, 90% and 79% of PASI 90 nonresponders had achieved PASI 90 after switching from adalimumab, ustekinumab or secukinumab, respectively. Durable improvements were also observed for PASI 100, Investigator\u2019s Global Assessment score 0\/1, body surface area affected by psoriasis \u2264 1%, absolute PASI \u2264 2, and Dermatology Life Quality Index 0\/1. Among PASI 90 responders, existing treatment responses were maintained or improved after switching to bimekizumab. The majority of TEAEs were mild or moderate. EAIRs were generally similar between active-comparator treatment periods and after switching to bimekizumab. EAIRs typically decreased with a longer duration of bimekizumab exposure.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>High proportions of patients who did not adequately respond to adalimumab, ustekinumab or secukinumab achieved high levels of skin clearance after switching to bimekizumab. Bimekizumab was well tolerated and there were no new safety findings.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/bjd\/ljac089","type":"journal-article","created":{"date-parts":[[2023,1,20]],"date-time":"2023-01-20T14:19:57Z","timestamp":1674224397000},"page":"330-340","source":"Crossref","is-referenced-by-count":33,"title":["Bimekizumab efficacy and safety in patients with moderate-to-severe plaque psoriasis who switched from adalimumab, ustekinumab or secukinumab: results from phase III\/IIIb trials"],"prefix":"10.1093","volume":"188","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8042-7885","authenticated-orcid":false,"given":"Georgios","family":"Kokolakis","sequence":"first","affiliation":[{"name":"Psoriasis Research and Treatment Center, Department of Dermatology, Venereology and Allergology, Charit\u00e9-Universit\u00e4tsmedizin Berlin , Berlin , Germany"},{"name":"Freie Universit\u00e4t Berlin , Berlin , Germany"},{"name":"Humboldt-Universit\u00e4t zu Berlin , Berlin , Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2918-6481","authenticated-orcid":false,"given":"Richard B","family":"Warren","sequence":"additional","affiliation":[{"name":"Dermatology Centre, Salford Royal NHS Foundation Trust, Manchester NIHR Biomedical Research Centre, The University of Manchester , Manchester , UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8394-2057","authenticated-orcid":false,"given":"Bruce","family":"Strober","sequence":"additional","affiliation":[{"name":"Yale University , New Haven, CT , USA"},{"name":"Central Connecticut Dermatology Research , Cromwell, CT , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Blauvelt","sequence":"additional","affiliation":[{"name":"Oregon Medical Research Center , Portland, OR , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luis","family":"Puig","sequence":"additional","affiliation":[{"name":"Hospital de la Santa Creu i Sant Pau , Universitat Aut\u00f2noma de Barcelona, Barcelona , Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akimichi","family":"Morita","sequence":"additional","affiliation":[{"name":"Nagoya City University Graduate School of Medical Sciences , Nagoya , Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8926-0113","authenticated-orcid":false,"given":"Melinda","family":"Gooderham","sequence":"additional","affiliation":[{"name":"SKiN Centre for Dermatology, Probity Medical Research , Peterborough, ON , Canada"},{"name":"Queen\u2019s University , Kingston, ON , Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"K\u00f6rber","sequence":"additional","affiliation":[{"name":"Hautaerzte Rue143 , Essen , Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Veerle","family":"Vanvoorden","sequence":"additional","affiliation":[{"name":"UCB Pharma , Brussels , Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maggie","family":"Wang","sequence":"additional","affiliation":[{"name":"UCB Pharma , Morrisville, NC , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dirk","family":"de Cuyper","sequence":"additional","affiliation":[{"name":"UCB Pharma , Brussels , Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cynthia","family":"Madden","sequence":"additional","affiliation":[{"name":"UCB Pharma , Morrisville, NC , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natalie","family":"Nunez Gomez","sequence":"additional","affiliation":[{"name":"UCB Pharma , Monheim , Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Lebwohl","sequence":"additional","affiliation":[{"name":"Icahn School of Medicine at Mount Sinai , New York, NY , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2022,11,29]]},"reference":[{"key":"2023100620080810300_ljac089-B1","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1016\/S0140-6736(19)31772-6","article-title":"Psoriasis biologics: a new era of choice","volume":"394","author":"Mahil","year":"2019","journal-title":"Lancet"},{"key":"2023100620080810300_ljac089-B2","article-title":"Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis","volume":"1","author":"Sbidian","year":"2020","journal-title":"Cochrane Database Syst Rev"},{"key":"2023100620080810300_ljac089-B3","doi-asserted-by":"crossref","first-page":"e14944","DOI":"10.1111\/dth.14944","article-title":"Investigation of prevalence of biologic use and discontinuation rates in moderate-to-severe psoriasis patients in Newfoundland and Labrador using real-world data","volume":"34","author":"Gulliver","year":"2021","journal-title":"Dermatol Ther"},{"key":"2023100620080810300_ljac089-B4","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1007\/s40261-017-0603-3","article-title":"A review of switching biologic agents in the treatment of moderate-to-severe plaque psoriasis","volume":"38","author":"Hu","year":"2018","journal-title":"Clin Drug Investig"},{"key":"2023100620080810300_ljac089-B5","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1111\/1346-8138.13860","article-title":"Switching of biologics in psoriasis: reasons and results","volume":"44","author":"Honda","year":"2017","journal-title":"J Dermatol"},{"key":"2023100620080810300_ljac089-B6","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1016\/S0140-6736(21)00184-7","article-title":"Therapeutics targeting the IL-23 and IL-17 pathway in psoriasis","volume":"397","author":"Ghoreschi","year":"2021","journal-title":"Lancet"},{"key":"2023100620080810300_ljac089-B7","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1007\/s40259-019-00355-4","article-title":"Adalimumab biosimilars in Europe: an overview of the clinical evidence","volume":"33","author":"Bellinvia","year":"2019","journal-title":"BioDrugs"},{"key":"2023100620080810300_ljac089-B8","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1177\/2040622318772705","article-title":"Safety and tolerability of adalimumab for the treatment of psoriasis: a review summarizing 15 years of real-life experience","volume":"9","author":"Sator","year":"2018","journal-title":"Ther Adv Chronic Dis"},{"key":"2023100620080810300_ljac089-B9","author":"European Medicines Agency"},{"key":"2023100620080810300_ljac089-B10","author":"European Medicines Agency"},{"key":"2023100620080810300_ljac089-B11","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1111\/bjd.19494","article-title":"Characteristics modifying response to biological treatments for psoriasis: considering subgroups in network meta-analysis","volume":"184","author":"Wade","year":"2021","journal-title":"Br J Dermatol"},{"key":"2023100620080810300_ljac089-B12","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1136\/annrheumdis-2017-212127","article-title":"Dual IL-17A and IL-17F neutralisation by bimekizumab in psoriatic arthritis: evidence from preclinical experiments and a randomised placebo-controlled clinical trial that IL-17F contributes to human chronic tissue inflammation","volume":"77","author":"Glatt","year":"2018","journal-title":"Ann Rheum Dis"},{"key":"2023100620080810300_ljac089-B13","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1007\/s12016-018-8702-3","article-title":"The immunologic role of IL-17 in psoriasis and psoriatic arthritis pathogenesis","volume":"55","author":"Blauvelt","year":"2018","journal-title":"Clin Rev Allergy Immunol"},{"key":"2023100620080810300_ljac089-B14","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1056\/NEJMoa2102388","article-title":"Bimekizumab versus adalimumab in plaque psoriasis","volume":"385","author":"Warren","year":"2021","journal-title":"N Engl J Med"},{"key":"2023100620080810300_ljac089-B15","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1016\/S0140-6736(21)00125-2","article-title":"Bimekizumab versus ustekinumab for the treatment of moderate to severe plaque psoriasis (BE VIVID): efficacy and safety from a 52-week, multicentre, double-blind, active comparator and placebo controlled phase 3 trial","volume":"397","author":"Reich","year":"2021","journal-title":"Lancet"},{"key":"2023100620080810300_ljac089-B16","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1056\/NEJMoa2102383","article-title":"Bimekizumab versus secukinumab in plaque psoriasis","volume":"385","author":"Reich","year":"2021","journal-title":"N Engl J Med"},{"key":"2023100620080810300_ljac089-B17","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1007\/s00403-019-01907-y","article-title":"Successful intra-class switching among IL-17 antagonists: a multicentre, multinational, retrospective study","volume":"311","author":"Gasslitter","year":"2019","journal-title":"Arch Dermatol Res"},{"key":"2023100620080810300_ljac089-B18","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.jaad.2018.01.003","article-title":"Efficacy and safety of switching to ixekizumab in secukinumab nonresponders with plaque psoriasis: a multicenter retrospective study of interleukin 17A antagonist therapies","volume":"79","author":"Georgakopoulos","year":"2018","journal-title":"J Am Acad Dermatol"},{"key":"2023100620080810300_ljac089-B19","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.jaad.2016.03.026","article-title":"Clinical meaningfulness of complete skin clearance in psoriasis","volume":"75","author":"Strober","year":"2016","journal-title":"J Am Acad Dermatol"},{"key":"2023100620080810300_ljac089-B20","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1001\/jamadermatol.2022.1185","article-title":"Bimekizumab safety in patients with moderate to severe plaque psoriasis: Pooled results from phase 2 and phase 3 randomized clinical trials","volume":"158","author":"Gordon","year":"2022","journal-title":"JAMA Dermatol"},{"key":"2023100620080810300_ljac089-B21","doi-asserted-by":"crossref","DOI":"10.4049\/jimmunol.1202924","article-title":"Cutting edge: IL-17\u2013secreting innate lymphoid cells are essential for host defense against fungal infection","volume":"190","author":"Gladiator","year":"2013","journal-title":"J Immunol"},{"key":"2023100620080810300_ljac089-B22","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1038\/mi.2014.57","article-title":"IL-17-mediated antifungal defense in the oral mucosa is independent of neutrophils","volume":"8","author":"Trautwein-Weidner","year":"2015","journal-title":"Mucosal Immunol"}],"container-title":["British Journal of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/bjd\/advance-article-pdf\/doi\/10.1093\/bjd\/ljac089\/48950284\/ljac089.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/bjd\/article-pdf\/188\/3\/330\/51918914\/ljac089.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/bjd\/article-pdf\/188\/3\/330\/51918914\/ljac089.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,6]],"date-time":"2023-10-06T20:13:01Z","timestamp":1696623181000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/bjd\/article\/188\/3\/330\/6850554"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11,29]]},"references-count":22,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2022,11,29]]},"published-print":{"date-parts":[[2023,2,22]]}},"URL":"https:\/\/doi.org\/10.1093\/bjd\/ljac089","relation":{},"ISSN":["0007-0963","1365-2133"],"issn-type":[{"value":"0007-0963","type":"print"},{"value":"1365-2133","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2023,3,1]]},"published":{"date-parts":[[2022,11,29]]}}}